CoChat
Cited by 176

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation

Open access
Sandmann, Frank G, Davies, Nicholas G, Vassall, Anna, Edmunds, W John, Jit, Mark, Sun, Fiona Yueqian, Villabona-Arenas, C Julian, Nightingale, Emily S, Showering, Alicia, Knight, Gwenan M, Sherratt, Katharine, Liu, Yang, Abbas, Kaja, Funk, Sebastian, Endo, Akira, Hellewell, Joel, Rosello, Alicia, Lowe, Rachel, Quaife, Matthew, Gimma, Amy, Brady, Oliver, Williams, Jack, Procter, Simon R, Eggo, Rosalind M, Chan, Yung-Wai Desmond, Munday, James D, Barnard, Rosanna C, Gore-Langton, Georgia R, Bosse, Nikos I, Waterlow, Naomi R, Diamond, Charlie, Russell, Timothy W, Medley, Graham, Flasche, Stefan, Atkins, Katherine E, Prem, Kiesha, Simons, David, Auzenbergs, Megan, Tully, Damien C, Jarvis, Christopher I, van Zandvoort, Kevin, Abbott, Sam, Pearson, Carl A B, Jombart, Thibaut, Meakin, Sophie R, Foss, Anna M, Kucharski, Adam J, Quilty, Billy J, Gibbs, Hamish P, Clifford, Samuel, Klepac, Petra · 2021 · The Lancet Infectious Diseases

Published version of a preprint

Abstract

Abstract Background In response to the coronavirus disease 2019 (COVID-19), the UK adopted mandatory physical distancing measures in March 2020. Vaccines against the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may become available as early as late 2020. We explored the health and economic value of introducing SARS-CoV-2 immunisation alongside physical distancing scenarios in the UK. Methods We used an age-structured dynamic-transmission and economic model to explore different scenarios of immunisation programmes over ten years. Assuming vaccines are effective in 5-64 year olds, we compared vaccinating 90% of individuals in this age group to no vaccination. We assumed either vaccine effectiveness of 25% and 1-year protection and 90% re-vaccinated annually, or 75% vaccine effectiveness and 10-year protection and 10% re-vaccinated annually. Natural immunity was assumed to last 45 weeks in the base case. We also explored the additional impact of physical distancing. We considered benefits from disease prevented in terms of quality-adjusted life-years (QALYs), and costs to the healthcare payer versus the national economy. We discounted at 3.5% annually and monetised health impact at £20,000 per QALY to obtain the net monetary value, which we explored in sensitivity analyses. Findings Without vaccination and physical distancing, we estimated 147.9 million COVID-19 cases (95% uncertainty interval: 48.5 million, 198.7 million) and 2.8 million (770,000, 4.2 million) deaths in the UK over ten years. Vaccination with 75% vaccine effectiveness and 10-year protection may stop community transmission entirely for several years, whereas SARS-CoV-2 becomes endemic without highly effective vaccines. Introducing vaccination compared to no vaccination leads to economic gains (positive net monetary value) of £0.37 billion to +£1.33 billion across all physical distancing and vaccine effectiveness scenarios from the healthcare perspective, but net monetary values of physical distancing scenarios may be negative from societal perspective if the daily national economy losses are persistent and large. Interpretation Our model findings highlight the substantial health and economic value of introducing SARS-CoV-2 vaccination. Given uncertainty around both characteristics of the eventually licensed vaccines and long-term COVID-19 epidemiology, our study provides early insights about possible future scenarios in a post-vaccination era from an economic and epidemiological perspective. Research in Context Evidence before this study We searched PubMed and medRxiv for economic evaluations of SARS-CoV-2 vaccines with the search string (coronavirus OR COVID OR SARS-CoV-2) AND (vaccin* OR immunisation) AND ((economic evaluation) OR (cost effectiveness analysis)) AND 2020[dp] on September 21, 2020, with no language restrictions. We found one pre-print that valued health outcomes in monetary terms and explored the additional impact of vaccines in a cost-benefit analysis of physical distancing for the USA; no study focused on vaccines in a full economic evaluation. Added value of this study With a growing number of vaccine candidates under development and having entered clinical trials, our study is to our knowledge the first to explore the health and economic value of introducing a national SARS-CoV-2 immunisation programme. A programme with high vaccine effectiveness and long-lasting protection may stop the community transmission entirely for a couple of years, but even a vaccine with 25% vaccine effectiveness is worthwhile to use; even at short-lived natural and vaccine-induced protections. After an initial lockdown, voluntary physical distancing as a sole strategy risks a large second epidemic peak, unless accompanied by highly effective immunisation. Compared to no vaccination, introducing vaccination leads to positive net monetary value across physical distancing scenarios from the healthcare perspective, subject to the long-run vaccine price and cost-effectiveness of other treatments (e.g. new drugs). The net monetary value of immunisation decreases if vaccine introduction is delayed, natural immunity is long or vaccine-induced protection is short. Intermittent physical distancing leads to negative net benefits from the perspective of the wider economy if the daily national income losses are persistent and large. Implications of all the available evidence Our model findings highlight the health and economic value of introducing SARS-CoV-2 vaccination to control the COVID-19 epidemic. Despite the many uncertainties, continued physical distancing may be needed to reduce community transmission until vaccines with sufficiently high vaccine effectiveness and long-lasting protection are available. Our study provides first broad health-economic insights rather than precise quantitative projections given the many uncertainties and unknown characteristics of the vaccine candidates and aspects of the long-term COVID-19

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(21)00079-7

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 25

  1. Zhu, 2020, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med, 382, 727, 10.1056/NEJMoa2001017 · DOI · Paper page
  2. Islam, 2020, Physical distancing interventions and incidence of coronavirus disease 2019: natural experiment in 149 countries, BMJ, 370
  3. Jit, 2020, Estimating number of cases and spread of coronavirus disease (COVID-19) using critical care admissions, United Kingdom, February to March 2020, Euro Surveill, 25, 10.2807/1560-7917.ES.2020.25.18.2000632 · doi:10.2807/1560-7917.es.2020.25.18.2000632
  4. Orr, 2015, Reconciling cost-effectiveness with the rule of rescue: the institutional division of moral labour, Theory Decis, 78, 525, 10.1007/s11238-014-9434-3 · doi:10.1007/s11238-014-9434-3
  5. Mahase, 2020, Covid-19: What do we know about the late stage vaccine candidates?, BMJ, 371
  6. Davies, 2020, Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study, Lancet Public Health, 5, e375, 10.1016/S2468-2667(20)30133-X · DOI · Paper page
  7. Poland, 2020, SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates, Lancet, 396, 1595, 10.1016/S0140-6736(20)32137-1 · DOI · Paper page
  8. Huang, 2020, A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity, Nat Commun, 11, 10.1038/s41467-020-18450-4 · DOI · Paper page
  9. Voysey, 2021, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, Lancet, 397, 99, 10.1016/S0140-6736(20)32661-1 · DOI · Paper page
  10. Krause, 2020, COVID-19 vaccine trials should seek worthwhile efficacy, Lancet, 396, 741, 10.1016/S0140-6736(20)31821-3 · DOI
  11. 2021, COVID-19: the green book, chapter 14a
  12. Claxton, 1999, The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies, J Health Econ, 18, 341, 10.1016/S0167-6296(98)00039-3 · DOI · Paper page
  13. Pronker, 2013, Risk in vaccine research and development quantified, PLoS One, 8, 10.1371/journal.pone.0057755 · DOI · Paper page
  14. Schonberger, 2020, Cost benefit analysis of limited reopening relative to a herd immunity strategy or shelter in place for SARS-CoV-2 in the United States, medRxiv
  15. Padula, 2020, Economic value of treatment and vaccine to address the COVID-19 pandemic: a US cost-effectiveness and budget impact analysis, SSRN, 10.2139/ssrn.3586694 · doi:10.2139/ssrn.3586694
  16. Saad-Roy, 2020, Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years, Science, 370, 811, 10.1126/science.abd7343 · DOI · Paper page
  17. Sandmann, 2018, Estimating the opportunity costs of bed-days, Health Econ, 27, 592, 10.1002/hec.3613 · DOI
  18. O'Brien, 2002, Is there a kink in consumers' threshold value for cost-effectiveness in health care?, Health Econ, 11, 175, 10.1002/hec.655 · DOI
  19. Chilton, 2020, Beyond COVID-19: How the ‘dismal science’ can prepare us for the future, Health Econ, 29, 851, 10.1002/hec.4114 · doi:10.1002/hec.4114
  20. Wang, 2020, Modelling Covid-19 under uncertainty: what can we expect?, Eur J Health Econ, 21, 665, 10.1007/s10198-020-01202-y · DOI
  21. Sud, 2020, Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study, Lancet Oncol, 21, 1035, 10.1016/S1470-2045(20)30392-2 · DOI · Paper page
  22. Abbas, 2020, Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefit–risk analysis of health benefits versus excess risk of SARS-CoV-2 infection, Lancet Glob Health, 8, e1264, 10.1016/S2214-109X(20)30308-9 · DOI · Paper page
  23. Saxena, 2020, Routine vaccination during covid-19 pandemic response, BMJ, 369
  24. McDonald, 2020, Early impact of the coronavirus disease (COVID-19) pandemic and physical distancing measures on routine childhood vaccinations in England, January to April 2020, Euro Surveill, 25, 10.2807/1560-7917.ES.2020.25.19.2000848 · DOI · Paper page
  25. Lo, 2005, Respiratory infections during SARS outbreak, Hong Kong, 2003, Emerg Infect Dis, 11, 1738, 10.3201/eid1111.050729 · DOI

Cited by

See all 176

Metadata

Authors
Sandmann, F. G., Davies, N. G., Vassall, A., Edmunds, W. J., Jit, M., Sun, F. Y., Villabona-Arenas, C. J., Nightingale, E. S., Showering, A., Knight, G. M., Sherratt, K., Liu, Y., Abbas, K., Funk, S., Endo, A., Hellewell, J., Rosello, A., Lowe, R., Quaife, M., Gimma, A., Brady, O., Williams, J., Procter, S. R., Eggo, R. M., Chan, Y.-W. D., Munday, J. D., Barnard, R. C., Gore-Langton, G. R., Bosse, N. I., Waterlow, N. R., Diamond, C., Russell, T. W., Medley, G., Flasche, S., Atkins, K. E., Prem, K., Simons, D., Auzenbergs, M., Tully, D. C., Jarvis, C. I., van Zandvoort, K., Abbott, S., Pearson, C. A. B., Jombart, T., Meakin, S. R., Foss, A. M., Kucharski, A. J., Quilty, B. J., Gibbs, H. P., Clifford, S., & Klepac, P.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2021-07
Volume
21
Issue
7
Pages
962-974
ISSN
1473-3099 (ISSN-L)
OpenAlex
W3088660694
Cited by
176
References
10
FWCI
14.70
Type
journal article
Language
en
Update notices
erratum (2021-10-01)
Open access
hybrid
Licence
Funders
  • Department of Health and Social Care
  • Department for International Development, UK Government
  • Public Health England
  • Biotechnology and Biological Sciences Research Council (BB/M009513/1, INV-001754)
  • Heiwa Nakajima Foundation (16/136/46, 16/137/109)
  • Economic and Social Research Council (ES/P010873/1)
  • Horizon 2020 (101003688)
  • National Institute for Health and Care Research
  • National Institute for Health Research Health Protection Research Unit (NIHR200929)
  • European Research Council (757699)
  • Medical Research Council (MC_PC_19065, MR/N013638/1, MR/P014658/1)
  • Royal Society (RP\EA\180004)
  • Bill and Melinda Gates Foundation (INV-003174)
  • Research Councils UK
  • London School of Hygiene and Tropical Medicine (NIHR200908)
  • Imperial College London
  • Wellcome Trust
  • European Commission

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation. https://app.cochat.ai/papers/10.1016/s1473-3099(21)00079-7
The paper
Sandmann, F. G., Davies, N. G., Vassall, A., Edmunds, W. J., Jit, M., Sun, F. Y., Villabona-Arenas, C. J., Nightingale, E. S., Showering, A., Knight, G. M., Sherratt, K., Liu, Y., Abbas, K., Funk, S., Endo, A., Hellewell, J., Rosello, A., Lowe, R., Quaife, M., . . . Klepac, P. (2021). The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(21)00079-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.